Lv1
18 积分 2023-08-31 加入
Evaluation of external radiation exposure in patients treated with 177Lu-PSMA and radiation safety assessment of the patient caregivers
5小时前
待确认
Evaluation of external radiation exposure in patients treated with 177Lu-PSMA and radiation safety assessment of the patient caregivers
1天前
已完结
Predicting benefit from [177Lu]Lu-PSMA-617 therapy: what do we need to know?
1个月前
已完结
TheraP: a randomized phase 2 trial of 177Lu‐PSMA‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)
1个月前
已完结
A First-in-Human Study of the Radiopharmaceutical [225Ac]-FPI-2068 in Patients (pts) with Advanced Solid Tumors
1个月前
已完结
68Ga‐PSMA PET/CT false positive liver metastasis prior to radical prostatectomy
3个月前
已完结
Short-course 177Lu-PSMA-617 Radioligand Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer: Time to Take the Leap?
3个月前
已完结
Theranostic Potential of [68Ga]Ga/[177Lu]Lu-LNC1013: A Dual-Purpose Ligand for Cancer Imaging and Radionuclide Therapy
3个月前
已完结
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
3个月前
已完结
Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial
3个月前
已完结
皖公网安备34019202002308
